Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60dae4ecb78c9f499de06dec2cdcfb00 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate |
2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6daa3e54d22a3e3707c97258858ac272 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6525ddb1c9f0aa729cda7b45da93bc6a |
publicationDate |
2010-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2222869-A1 |
titleOfInvention |
Screening method for agents suitable for therapy of alzheimer's disease |
abstract |
Described is a method of screening for therapeutic agents for the prophylaxis and therapy of Alzheimer's disease (AD), wherein agents that (i) do not interfere with the biological activity of gamma- secretase, (ii) do not exhibit cytotoxicity, (iii) lead to reduced amounts of Abeta42 and (iv) are capable of binding to an APP-GxxxG motif thereby weakening or inhibiting dimerization of the APP transmembrane sequence are suitable for prophylaxis or treatment of AD. |
priorityDate |
2007-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |